Reduced selenium-binding protein 1 is associated with poor survival rate in gastric carcinoma.
Human selenium-binding protein 1 (SBP1) is known to play a key role in the development and progression of many cancers. The role of SBP1 expression in gastric carcinoma (GC) is far from being fully established. The aim of the present study was to evaluate the expression of SBP1 in GC and correlate the findings with several clinicopathological features and prognosis. Tissue samples from 65 patients treated by gastric resection for GC with clinical stage II and III were used. Each sample was matched with the corresponding nonneoplastic epithelia tissues removed during the same surgery. Reverse transcriptase-polymerase chain reaction, immunostaining and Western blot analyses were used to detect the expression of SBP1 at the mRNA and protein levels, respectively. The associations between SBP1 expressions and clinicopathological features were analyzed. Expressions of SBP1 at both mRNA and protein levels were significantly lower in GC than those in the corresponding nonneoplastic epithelia tissues (P = 0.000). SBP1-negative expression had a significant relationship with high clinical stage (P = 0.038). Prognosis of SBP1-negative patients was significantly poorer than that of SBP1-positive patients (P = 0.001), and multivariate analysis further confirmed that SBP1 was an independent prognostic factor (P = 0.004). Thus, down-regulation of SBP1 may play a key role in the tumorigenic process of human GC. The correlation of SBP1 reduction in GC with clinical stage and survival proposes a prognostic role in GC.